6,985 Shares in Henry Schein, Inc. $HSIC Purchased by North Star Asset Management Inc.

North Star Asset Management Inc. bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 6,985 shares of the company’s stock, valued at approximately $583,000.

Other institutional investors have also added to or reduced their stakes in the company. Buckland Partners Management Co LLC acquired a new stake in Henry Schein in the second quarter valued at approximately $1,036,000. Heartland Advisors Inc. acquired a new position in shares of Henry Schein during the 4th quarter worth $9,070,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Henry Schein by 10,448.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 42,193 shares of the company’s stock worth $3,189,000 after purchasing an additional 41,793 shares during the last quarter. K.J. Harrison & Partners Inc bought a new position in shares of Henry Schein during the 1st quarter valued at $1,253,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Henry Schein by 15.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 115,279 shares of the company’s stock valued at $8,856,000 after purchasing an additional 15,765 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 0.8%

Shares of HSIC stock opened at $89.52 on Friday. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a market cap of $9.98 billion, a PE ratio of 26.10, a price-to-earnings-growth ratio of 1.72 and a beta of 0.80. The stock has a 50 day moving average of $86.68 and a 200-day moving average of $80.00.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. Henry Schein’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts predict that Henry Schein, Inc. will post 5.36 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Barrington Research set a $104.00 target price on shares of Henry Schein in a research report on Wednesday, August 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Citigroup reissued a “buy” rating and set a $112.00 price objective (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. BMO Capital Markets assumed coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price objective on the stock. Finally, Mizuho reduced their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $92.93.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.